Function
Locations
Generates glyoxylate (the oxalate precursor); a therapeutic target for the primary hyperoxalurias (its loss is protective).
Glyoxylate is a reactive two-carbon metabolite that, if not detoxified, is oxidised to oxalate — an end product that cannot be further metabolised and precipitates as insoluble calcium oxalate, damaging the kidney. Hepatic glyoxylate handling therefore determines systemic oxalate load, and its enzymes define the primary hyperoxalurias. Glyoxylate arises from two main sources: peroxisomal glycolate oxidase (HAO1), an FMN enzyme that oxidises glycolate to glyoxylate (generating H2O2), and mitochondrial 4-hydroxy-2-oxoglutarate aldolase (HOGA1), the terminal enzyme of hydroxyproline catabolism, which cleaves 4-hydroxy-2-oxoglutarate to glyoxylate and pyruvate. Glyoxylate is then detoxified by two routes: the peroxisomal, pyridoxal-phosphate-dependent alanine-glyoxylate aminotransferase (AGXT/AGT) transaminates it back to glycine (using L-alanine), and the cytosolic NADPH- dependent glyoxylate/hydroxypyruvate reductase (GRHPR) reduces it to glycolate; a mitochondrial aminotransferase (AGXT2) provides an additional transamination route (and also degrades the NO-synthase inhibitors ADMA/SDMA). When detoxification fails, glyoxylate is oxidised to oxalate. Inherited defects each cause a primary hyperoxaluria: PH1 (AGXT), PH2 (GRHPR) and PH3 (HOGA1); HAO1, which makes glyoxylate, is a validated drug target (the siRNA lumasiran silences HAO1 to lower oxalate).
All recommended fields populated.
✗ none found
No MODULE:glyoxylate_oxalate_metabolism deep-research report alongside the module YAML.
✓ every leaf node grounds to a representative protein.
✓ every declared conforms_to bundle matches its template motif.
5 complete review(s) · 0 with deep research · 0 missing review · 5 reviewed but lacking deep research
| Gene | Review | Complete | Deep research |
|---|---|---|---|
| AGXT P21549 | ✓ | ✓ | ✗ |
| AGXT2 Q9BYV1 | ✓ | ✓ | ✗ |
| GRHPR Q9UBQ7 | ✓ | ✓ | ✗ |
| HAO1 Q9UJM8 | ✓ | ✓ | ✗ |
| HOGA1 Q86XE5 | ✓ | ✓ | ✗ |
Glyoxylate/oxalate metabolism, grounded to the human enzymes HAO1 (UniProtKB:Q9UJM8, GO:0003973, EC 1.1.3.15), HOGA1 (Q86XE5, GO:0008700, EC 4.1.3.16), AGXT (P21549, GO:0008453, EC 2.6.1.44), GRHPR (Q9UBQ7, GO:0030267, EC 1.1.1.79) and AGXT2 (Q9BYV1, GO:0008453, EC 2.6.1.44). GO molecular-function/BP/location terms were taken from the completed human gene reviews and verified against the local go.db; Reactome reaction ids/titles were verified against the local reactome cache. Each step uses a PANTHER family selector (five distinct families — these enzymes are not paralogs). The pathway is a compartmentalised generation/detoxification balance: glyoxylate is generated in the peroxisome (HAO1 from glycolate) and mitochondrion (HOGA1 from hydroxyproline), and detoxified by transamination to glycine (peroxisomal AGXT, mitochondrial AGXT2) or reduction to glycolate (cytosolic GRHPR); the AGT/glyoxylate and glycolate/GRHPR pools are exchanged across compartments. When these routes are overwhelmed, glyoxylate is oxidised to oxalate (in part by HAO1's minor glyoxylate- oxidase activity and LDH), which precipitates as calcium oxalate. Disorders: primary hyperoxaluria type 1 (AGXT), type 2 (GRHPR) and type 3 (HOGA1); HAO1 is the lumasiran drug target and AGXT2 a modifier (also of plasma ADMA / cardiovascular-renal phenotypes). Glycine produced by AGXT/AGXT2 feeds one-carbon/glycine metabolism (the glycine-cleavage module).
Generates glyoxylate (the oxalate precursor); a therapeutic target for the primary hyperoxalurias (its loss is protective).
Terminal enzyme of hydroxyproline catabolism; generates mitochondrial glyoxylate. Deficiency = primary hyperoxaluria type 3 (PH3).
Principal glyoxylate detoxification route; deficiency = primary hyperoxaluria type 1 (PH1, the most severe). A common variant mistargets AGT to mitochondria.
Cytosolic glyoxylate detoxification (reduction); deficiency = primary hyperoxaluria type 2 (PH2).
Mitochondrial glyoxylate detoxification and dimethylarginine (ADMA/SDMA) metabolism; a modifier of oxalate and cardiovascular/renal phenotypes.